-
Mashup Score: 0FDA grants orphan drug designation to multitargeted T-cell therapy for pancreatic cancer - 2 year(s) ago
The FDA granted orphan drug designation to MT-601, an investigational T-cell immunotherapy, for treatment of advanced or metastatic pancreatic adenocarcinoma.MT-601 (Marker Therapeutics) is an autologous, nongene-edited T-cell therapy composed of cytotoxic T lymphocyte lines that target PRAME, SSX2, MAGEA4, NY-ESO-1 and Survivin proteins on the surface of cancer cells.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
The FDA granted orphan drug designation to CNCT19, a chimeric antigen receptor T-cell therapy for the treatment of relapsed or refractory acute lymphoblastic leukemia.CNCT19 (CASI Pharmaceuticals and Juventas Cell Therapy) is an autologous, gene-edited CAR T-cell therapy that targets the CD19 protein on the surface of cancer cells.
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
FDA grants orphan drug designation to #CARTcell therapy from CASI Pharmaceuticals/Juventas Cell Therapy for advanced acute lymphoblastic #leukemia https://t.co/GczA2O29sv #CellTherapyNext
-
-
Mashup Score: 0FDA grants fast track, RMAT designations to bispecific CAR-T for non-Hodgkin lymphoma - 2 year(s) ago
The FDA granted fast track and regenerative medicine advanced therapy designations to C-CAR039, a chimeric antigen receptor T-cell therapy in development for treatment of relapsed or refractory diffuse large B cell lymphoma.C-CAR039 (Cellular Biomedicine Group, CBMG) is an autologous, gene-edited, bispecific CAR T-cell therapy that targets both CD19 and CD20 proteins on the surface of cancer
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
C-CAR039, a bispecific CAR-T, granted fast track & RMAT designations by FDA for non-Hodgkin #lymphoma https://t.co/sa0iwouzjq @CellBioMedGroup #CellTherapyNext
-
-
Mashup Score: 0FDA grants fast track, RMAT designations to bispecific CAR-T for non-Hodgkin lymphoma - 2 year(s) ago
The FDA granted fast track and regenerative medicine advanced therapy designations to C-CAR039, a chimeric antigen receptor T-cell therapy in development for treatment of relapsed or refractory diffuse large B cell lymphoma.C-CAR039 (Cellular Biomedicine Group, CBMG) is an autologous, gene-edited, bispecific CAR T-cell therapy that targets both CD19 and CD20 proteins on the surface of cancer
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
C-CAR039, a bispecific CAR-T, granted fast track & RMAT designations by FDA for non-Hodgkin #lymphoma https://t.co/CNRLeQK8jC @CellBioMedGroup #CellTherapyNext
-
-
Mashup Score: 2
The FDA granted regenerative medicine advanced therapy designation to CT041, a chimeric antigen receptor T-cell therapy for adults with relapsed or refractory gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.CT041 (CARsgen Therapeutics) is an autologous, gene-edited CAR T-cell therapy that targets claudin 18.2, a stomach-specific isoform of claudin 18 that is highly expressed in
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
FDA grants RMAT designation to @CARsgen_Ther #CARTcell therapy for advanced gastric cancers https://t.co/kqABuUfjfJ #CellTherapyNext
-
-
Mashup Score: 0
The FDA granted regenerative medicine advanced therapy designation to CT041, a chimeric antigen receptor T-cell therapy for adults with relapsed or refractory gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.CT041 (CARsgen Therapeutics) is an autologous, gene-edited CAR T-cell therapy that targets claudin 18.2, a stomach-specific isoform of claudin 18 that is highly expressed in
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
FDA grants RMAT designation to @CARsgen_Ther #CARTcell therapy for advanced gastric cancers https://t.co/k3BzzA6XLd #CellTherapyNext
-
-
Mashup Score: 0FDA lifts clinical hold on Allogene’s CAR T-cell therapy trials - 2 year(s) ago
The FDA lifted its clinical hold on a series of trials that use Allogene Therapeutics’ AlloCAR T chimeric antigen receptor T-cell therapies, according to a press release from the manufacturer.Allogene announced the hold in October 2021 based on the report of one patient with pretreated stage IV follicular lymphoma who showed evidence of a chromosomal abnormality after receiving the
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
FDA lifts hold on 5 clinical trials for @AllogeneTx AlloCAR T #CellTherapy https://t.co/GNv3AO7mKJ #CellTherapyNext
-
FDA lifts hold on 5 clinical trials for @AllogeneTx AlloCAR T #CellTherapy https://t.co/GaRHwtDOBG #CellTherapyNext
-
-
Mashup Score: 0
Younger Hispanic/Latinx patients face many barriers that may limit timely access to chimeric antigen receptor T-cell therapy trials for relapsed or refractory B-cell acute lymphoblastic leukemia, according to retrospective study results.The findings — presented at ASH Annual Meeting and Exposition — showed that younger patients referred to urban academic centers for CAR-T clinical
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
🎙“Traveling to receive #CARTcell therapy can be resource-intensive...Ultimately, it will be important to provide these life-saving therapies closer to home to allow for more children to have access” says Anurekha Hall, MD @seattlechildren https://t.co/LudJkwua6e #CellTherapyNext https://t.co/kWRNftzHuM
-
-
Mashup Score: 0
Younger Hispanic/Latinx patients face many barriers that may limit timely access to chimeric antigen receptor T-cell therapy trials for relapsed or refractory B-cell acute lymphoblastic leukemia, according to retrospective study results.The findings — presented at ASH Annual Meeting and Exposition — showed that younger patients referred to urban academic centers for CAR-T clinical
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎙“Traveling to receive #CARTcell therapy can be resource-intensive...Ultimately, it will be important to provide these life-saving therapies closer to home to allow for more children to have access” says Anurekha Hall, MD @seattlechildren https://t.co/UgioX0dMOt #CellTherapyNext https://t.co/aQUHi19SHt
-
-
Mashup Score: 0
Younger Hispanic/Latinx patients face many barriers that may limit timely access to chimeric antigen receptor T-cell therapy trials for relapsed or refractory B-cell acute lymphoblastic leukemia, according to retrospective study results.The findings — presented at ASH Annual Meeting and Exposition — showed that younger patients referred to urban academic centers for CAR-T clinical
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
Study from Consortium for Pediatric Cellular Immunotherapy shows younger Hispanic/Latinx patients face barriers to #CARTcell clinical trials https://t.co/LudJkwua6e #CellTherapyNext @seattlechildren @ChildrensNatl @ChildrensColo @ChildrensLA @UCSFChildrens @UCSFBenioffOAK https://t.co/Gyx1mtJVPp
-
MT-601, a multitarget T-cell therapy from @MRKRTherapeutic for pancreatic cancer, given orphan drug designation by FDA https://t.co/nqbuPsWNOB #oncology #CellTherapyNext